Medline Inc. (MDLN) 株式分析

企業概要

Medline Inc. is a prominent manufacturer of medical-surgical products that supplies hospitals, surgery centers, physician offices, post-acute facilities, and nursing home sites of care both domestically and internationally. The company operates within the Healthcare sector, specifically focusing on the Medical Instruments & Supplies industry, which is characterized by high regulatory standards and a reliance on consistent demand from healthcare providers. This entity employs approximately 45,000 individuals, reflecting its substantial operational footprint and labor-intensive production processes across its supply chain. With a market capitalization of $37.08 billion and trailing twelve-month revenue of $28.43 billion, the company demonstrates a scale that places it among the leading players in the global medical supplies market. These valuation figures indicate a mature yet expansive business model capable of generating significant economic value, supported by a robust workforce and extensive distribution network.

財務健全性

The company reported total revenue of $28.43 billion for the trailing twelve months, generating net income of $1.16 billion and EBITDA of $3.19 billion. The substantial gap between the revenue figure and net income reveals a cost structure heavily influenced by operating expenses, resulting in a profit margin of 4.1% that is typical for high-volume, low-margin manufacturing industries. Free cash flow stood at $791.25 million, indicating that the business generates sufficient liquidity to cover capital expenditures and maintain financial flexibility without relying on external financing. Analyzing the margins shows a gross margin of 26.4%, which reflects the pricing power and cost efficiency in sourcing raw materials and manufacturing medical instruments, while an operating margin of 5.7% highlights the impact of overhead costs such as sales, general, and administrative expenses. The balance sheet displays a cash position of $1.98 billion against total debt of $13.01 billion, resulting in a debt-to-equity ratio of 67.47, which suggests a leveraged capital structure rather than a conservative one. Despite the leverage, the current ratio of 4.29 indicates strong short-term liquidity, meaning the company holds more than four times the current assets required to meet its short-term liabilities. Return on equity is 6.5% and return on assets is 3.7%, metrics that reveal the efficiency with which management utilizes shareholder capital and total assets to generate profits.

バリュエーション評価

The trailing twelve-month P/E ratio is 31.95, while the forward P/E is estimated at 27.62, implying that the market expects earnings to grow in the future to bring the forward multiple closer to or below the trailing multiple. The price-to-book ratio stands at 3.46, indicating that the market values the company at a significant premium over its book value, reflecting intangible assets, brand strength, and growth prospects. Alternative valuation metrics include a price-to-sales ratio of 1.30 and an EV/EBITDA of 17.77, which provide context by valuing the firm relative to its sales revenue and enterprise earnings before interest, taxes, depreciation, and amortization. The stock has traded between a 52-week high of $50.88 and a 52-week low of $34.89, providing a reference range for current trading levels relative to recent volatility. Although the beta is listed as N/A, the wide spread between the 52-week high and low suggests the stock has experienced notable price fluctuations within the past year.

Growth & Income

Revenue growth year-over-year was 14.8%, while earnings growth year-over-year reached 1254.7%, indicating that earnings are expanding at a rate significantly faster than revenue, likely driven by one-time events, restructuring charges, or exceptional cost savings in the prior period. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, demonstrating a strategy of reinvesting all earnings back into the business to fund growth initiatives, acquisitions, or debt reduction rather than distributing cash to shareholders. This approach prioritizes capital allocation toward operational expansion and supply chain optimization over immediate income generation for investors. The overall growth and income profile is defined by double-digit revenue expansion and exceptional earnings per share growth, coupled with a capital preservation strategy that forgoes regular dividend distributions.